Why Investors Should Care About MindMed’s LSD Trial for Anxiety
MindMed will present preliminary results from a Phase 2a study treating Generalized Anxiety Disorder with LSD therapy next month.
Author: James Hallifax
Numinus Acquiring Novamind in First Major Psychedelics Merger
This deal will make Numinus the psychedelic medicines company with the highest revenue, though of course there is still a long road to profitability.
Mushrooms Have Their Own Language, New Study Suggests
The electric pulses could be organized into “trains” that resemble human words, and a vocabulary of “up to 50 words” appears to be present.
How to Enroll in a Psychedelic Clinical Trial in 5 Easy Steps
Interested in participating in a psychedelic study? Here’s an in-depth walk through guide so you can take actionable steps to make it happen.
5 Most Important Psychedelic Clinical Trials in 2022
Here’s why we think MAPS’ second Phase 3 MDMA trial is the most important psychedelic study of 2022, and 4 more that may have huge impacts.
Psilocybin Is Effective in Reducing Weight Gain, New Study Shows
NeonMind finds that its proprietary psilocybin has the ability to target visceral fat, effectively reducing weight gain in obese subjects.
Ketamine Study Suggests the Psychedelic Could Treat Parkinson’s Disease
PharmaTher evaluates safety, tolerability and efficacy of low-dose ketamine infusion for treatment of LID in Parkinson’s Disease patients.
Another Psychedelics Company Is Crashing
Core One Labs appears to be following in footsteps of Mind Cure, but that doesn’t mean the entire psychedelics industry is in trouble.
Is Small Pharma a Good Psychedelic Stock Investment?
Our resident Psychedelic Investor James Hallifax looks at the pros and cons of this Canadian-based company developing DMT for therapeutic use.
Can Psychedelics like MDMA Cure Eating Disorders?
Anyone who has ever suffered from an eating disorder, such…
End of content
End of content